New drug combo shows promise for tough lung cancer
NCT ID NCT04227028
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding bevacizumab to brigatinib can help people with ALK-positive non-small cell lung cancer whose disease has worsened on previous ALK-targeted therapy. The study enrolls just 5 patients and focuses on safety, side effects, and finding the best dose. It is too soon to know if the combination works better than existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brigatinib (a targeted therapy) and bevacizumab (a monoclonal antibody)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with ALK-positive lung cancer whose current therapy has stopped working.
- What could go wrong
- This is a very early, small Phase 1 trial with only 5 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy